Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer

Bhagelu R. Achyut, Ali S. Arbab

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Tumor microenvironment (TME) consists of several immune and nonimmune cell populations including tumor cells. For many decades, experimental studies have depicted profound contribution of TME toward cancer progression and metastasis development. Several therapeutic strategies have been tested against TME through preclinical studies and clinical trials. Unfortunately, most of them have shown transient effect, and have largely failed due to aggressive tumor growth and without improving survival. Solid tumors are known to have a strong myeloid component (eg, tumor-associated macrophages) in tumor development. Recent data suggest that therapeutic responses in tumor are characterized by alterations in immune cell signatures, including tumor-associated myeloid cells. Polarized tumor-associated myeloid cells (M1–M2) are critical in impairing therapeutic effect and promoting tumor growth. The present review is intended to compile all the literatures related to the emerging contribution of different populations of myeloid cells in the development of tumor and therapeutic failures. Finally, we have discussed targeting of myeloid cell populations as a combination therapy with chemo-, targeted-, or radiation therapies.

Original languageEnglish (US)
Pages (from-to)1047-1055
Number of pages9
JournalOncoTargets and Therapy
Volume9
DOIs
StatePublished - Mar 1 2016

Fingerprint

Tumor Microenvironment
Myeloid Cells
Neoplasms
Therapeutics
Population
Therapeutic Uses
Growth
Radiotherapy
Macrophages
Clinical Trials
Neoplasm Metastasis

Keywords

  • Antiangiogenic therapy
  • Macrophage polarization
  • Myeloid-derived suppressor cells
  • Radiation
  • Therapies
  • Tumor microenvironment
  • Tumor-associated macrophage

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. / Achyut, Bhagelu R.; Arbab, Ali S.

In: OncoTargets and Therapy, Vol. 9, 01.03.2016, p. 1047-1055.

Research output: Contribution to journalArticle

@article{3d497e3904624ff99546d796a09ca86a,
title = "Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer",
abstract = "Tumor microenvironment (TME) consists of several immune and nonimmune cell populations including tumor cells. For many decades, experimental studies have depicted profound contribution of TME toward cancer progression and metastasis development. Several therapeutic strategies have been tested against TME through preclinical studies and clinical trials. Unfortunately, most of them have shown transient effect, and have largely failed due to aggressive tumor growth and without improving survival. Solid tumors are known to have a strong myeloid component (eg, tumor-associated macrophages) in tumor development. Recent data suggest that therapeutic responses in tumor are characterized by alterations in immune cell signatures, including tumor-associated myeloid cells. Polarized tumor-associated myeloid cells (M1–M2) are critical in impairing therapeutic effect and promoting tumor growth. The present review is intended to compile all the literatures related to the emerging contribution of different populations of myeloid cells in the development of tumor and therapeutic failures. Finally, we have discussed targeting of myeloid cell populations as a combination therapy with chemo-, targeted-, or radiation therapies.",
keywords = "Antiangiogenic therapy, Macrophage polarization, Myeloid-derived suppressor cells, Radiation, Therapies, Tumor microenvironment, Tumor-associated macrophage",
author = "Achyut, {Bhagelu R.} and Arbab, {Ali S.}",
year = "2016",
month = "3",
day = "1",
doi = "10.2147/OTT.S102907",
language = "English (US)",
volume = "9",
pages = "1047--1055",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer

AU - Achyut, Bhagelu R.

AU - Arbab, Ali S.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Tumor microenvironment (TME) consists of several immune and nonimmune cell populations including tumor cells. For many decades, experimental studies have depicted profound contribution of TME toward cancer progression and metastasis development. Several therapeutic strategies have been tested against TME through preclinical studies and clinical trials. Unfortunately, most of them have shown transient effect, and have largely failed due to aggressive tumor growth and without improving survival. Solid tumors are known to have a strong myeloid component (eg, tumor-associated macrophages) in tumor development. Recent data suggest that therapeutic responses in tumor are characterized by alterations in immune cell signatures, including tumor-associated myeloid cells. Polarized tumor-associated myeloid cells (M1–M2) are critical in impairing therapeutic effect and promoting tumor growth. The present review is intended to compile all the literatures related to the emerging contribution of different populations of myeloid cells in the development of tumor and therapeutic failures. Finally, we have discussed targeting of myeloid cell populations as a combination therapy with chemo-, targeted-, or radiation therapies.

AB - Tumor microenvironment (TME) consists of several immune and nonimmune cell populations including tumor cells. For many decades, experimental studies have depicted profound contribution of TME toward cancer progression and metastasis development. Several therapeutic strategies have been tested against TME through preclinical studies and clinical trials. Unfortunately, most of them have shown transient effect, and have largely failed due to aggressive tumor growth and without improving survival. Solid tumors are known to have a strong myeloid component (eg, tumor-associated macrophages) in tumor development. Recent data suggest that therapeutic responses in tumor are characterized by alterations in immune cell signatures, including tumor-associated myeloid cells. Polarized tumor-associated myeloid cells (M1–M2) are critical in impairing therapeutic effect and promoting tumor growth. The present review is intended to compile all the literatures related to the emerging contribution of different populations of myeloid cells in the development of tumor and therapeutic failures. Finally, we have discussed targeting of myeloid cell populations as a combination therapy with chemo-, targeted-, or radiation therapies.

KW - Antiangiogenic therapy

KW - Macrophage polarization

KW - Myeloid-derived suppressor cells

KW - Radiation

KW - Therapies

KW - Tumor microenvironment

KW - Tumor-associated macrophage

UR - http://www.scopus.com/inward/record.url?scp=84959498999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959498999&partnerID=8YFLogxK

U2 - 10.2147/OTT.S102907

DO - 10.2147/OTT.S102907

M3 - Article

C2 - 27042097

AN - SCOPUS:84959498999

VL - 9

SP - 1047

EP - 1055

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -